Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that it has begun a preclinical toxicity study of its novel time-released, dosage-controlled ketamine formulation, designated as SP-26, for the treatment of fibromyalgia. About Silo Pharma Silo Pharma is a biotechnology startup that
Read More
Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently announced the development of a tea bag containing psilocybin for use in clinical research. If granted appropriate regulatory approvals, this could eventually be used as a treatment for clients in psychedelic-assisted therapy. Numinus strives to be at the cutting edge of psychedelic-assisted therapies
atai has administered the first dosage of their VLS-01 synthetic DMT drug
Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)
The nation’s largest ketamine therapy provider now offers complimentary patient resources supporting holistic mental health treatment. On Thursday, the largest ketamine therapy
Clinical-stage biotechnology Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) has strengthened their intellectual property portfolio with a new provisional patent designed to treat
